Infinity Bio Closes $8M Series A Financing
Deal News | Jun 18, 2025 | Illumina Ventures
Infinity Bio has successfully closed an $8 million Series A financing round led by Illumina Ventures. This investment will support Infinity Bio’s platform innovation, commercial scaling, and the development of new services. As part of their strategic growth plan, Infinity Bio has also acquired the assets of Serimmune, Inc. This acquisition is expected to enhance Infinity Bio's leadership in antibody reactome profiling, which is crucial for advancing their platform capabilities.
Sectors
- Biotechnology
- Venture Capital
Geography
- United States – The companies mentioned, including Infinity Bio and Serimmune, Inc., are based in the United States, and Illumina Ventures operates there as well.
Industry
- Biotechnology – Infinity Bio operates in the biotechnology sector, focusing on antibody reactome profiling, an advanced biotechnology field.
- Venture Capital – Illumina Ventures is a venture capital firm leading the Series A investment for Infinity Bio.
Financials
- $8 million – The total amount of Series A financing raised by Infinity Bio, led by Illumina Ventures.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Infinity Bio | Target Company | Company | Infinity Bio is involved in antibody reactome profiling and has recently secured Series A financing to expand its operations. |
| Illumina Ventures | Investing Company | Company | A venture capital firm that led the Series A funding round for Infinity Bio. |
| Serimmune, Inc. | Acquired Company | Company | Serimmune, Inc.'s assets have been acquired by Infinity Bio to bolster its capabilities in biotechnology. |